NuPharm Group, a leading European specialty pharma company focussed on the treatment of central nervous system (CNS) disorders, has today announced that Dr. Jörg-Thomas Dierks has been appointed Chief Executive Officer (CEO) effective immediately. Jörg is replacing Stephan Walz, who has decided to step down in order to pursue other activities.
Jörg brings 30 years of healthcare experience, having held several senior executive positions in the pharmaceutical industry. Most recently, he was the CEO of Meda, the Sweden-based specialty pharma company, a position he held from 2013. Before becoming CEO, Jörg was the Chief Operating Officer (COO) for Meda from 2005 to 2013 and also assumed the role of Chief Scientific Officer (CSO) for a period of time. He was instrumental in growing the business over many years and leading its sale to Mylan in 2016 for $10bn. Prior to Meda, Jörg was the COO of Viatris, a Germany-based pharmaceutical company.
Dr. Jörg-Thomas Dierks commented: “I am delighted to be joining NuPharm at an exciting time. The company has successfully created a European platform of scale and become a key player in the treatment of CNS diseases. I am looking forward to working alongside the management team to continue to build on the positive developments that have been made and lead the Company through its next phase of growth with the objective to make it a prominent European player in the CNS field.”
NuPharm was created through the strategic combination and integration of six specialty pharmaceutical companies: Neuraxpharm (Germany and Poland), Qualigen (Spain), FB Health (Italy), Laboratoire Biodim (France), as well as Laboratorios Lesvi and Inke (Spain), Following this, NuPharm now has direct market presence in the six largest EU markets and offers specialised B2B capabilities.
Arthur Brothag, member of the Board of Directors of NuPharm, commented: “I would like to thank Stephan on behalf of the whole NuPharm team for his contribution and leadership over the last two years. He has played an important role in building NuPharm into what it is today. We wish him all the very best in the future.
“I am very excited to welcome Jörg to NuPharm and look forward to working with him on consolidating NuPharm’s success further to the benefit of patients across Europe.”